MS Study Evaluating Safety and Efficacy of Two Doses of Fingolimod Versus Copaxone

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
The purpose of this study was to demonstrate that at least one dose (0.5 mg followed by 0.25 mg) of fingolimod is superior to glatiramer acetate 20 mg SC in reducing the ARR up to 12 months in patients with relapsing-remitting MS
Epistemonikos ID: 8e4734e2ca8c4cec2638fc8402af87abdd7e3917
First added on: Mar 30, 2022